PA
PHAT icon

PharVision Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

PharVision Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,968
Closed -$364K – 931
2025
Q3 		$364K Buy
+30,968
New +$320K 0.21% 118

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

PharVision Advisers's PHAT Position: Q4 2025 in Review

PharVision Advisers sold out of Phathom Pharmaceuticals (PHAT) in Q4 2025, closing a stake of 30,968 shares — an estimated $364K sold.

PharVision Advisers first reported a position in PHAT in Q3 2025 and held it in 1 quarter. The position peaked at $364K in Q3 2025. 172 funds tracked by Wall St. Rank hold PHAT as of Q4 2025.

  • PharVision Advisers reported no remaining Phathom Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 30,968 Phathom Pharmaceuticals shares in Q4 2025, an estimated $364K.
  • PharVision Advisers first reported a position in Phathom Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Phathom Pharmaceuticals position peaked at $364K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.